Cancer Clinical Trials

10,754 recruitingLast updated: July 27, 2026

There are 10,754 actively recruiting cancer clinical trials across 130 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 3, Early Phase 1, Phase 4. Top locations include New York, New York, United States, Houston, Texas, United States, Shanghai, Shanghai Municipality, China. Updated daily from ClinicalTrials.gov.


Cancer Trials at a Glance

10,754 actively recruiting trials for cancer are listed on ClinicalTrialsFinder across 6 cities in 130 countries. The largest study group is Phase 2 with 3,003 trials, with the heaviest enrollment activity in New York, Houston, and Shanghai. Lead sponsors running cancer studies include Fudan University, M.D. Anderson Cancer Center, and Memorial Sloan Kettering Cancer Center.

Treatments under study

About Cancer Clinical Trials

Looking for clinical trials for Cancer? There are currently 935 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 10,754 trials

Recruiting
Phase 3

MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)

Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC400 enrolled72 locationsNCT07431827
Recruiting
Phase 1

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

Advanced Breast CancerAdvanced Solid TumorsMetastatic Pancreatic Cancer+3 more
National Cancer Institute (NCI)116 enrolled2 locationsNCT04222413
Recruiting
Phase 3

A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)

Biliary Tract Cancer
Sichuan Baili Pharmaceutical Co., Ltd.538 enrolled1 locationNCT07582315
Recruiting
Phase 3

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

Stage IIIA Cervical Cancer FIGO 2018Stage IIIB Cervical Cancer FIGO 2018Locally Advanced Cervical Adenocarcinoma+5 more
National Cancer Institute (NCI)336 enrolled296 locationsNCT07061977
Recruiting
Phase 2Phase 3

Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

Gastroesophageal-junction CancerEsophageal AdenocarcinomaMetastatic Gastric Cancer+1 more
Pfizer840 enrolled69 locationsNCT07392892
Recruiting
Phase 1

A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer

Breast CancerInvasive Breast Cancer
Memorial Sloan Kettering Cancer Center60 enrolled7 locationsNCT05412225
Recruiting

Identifying Genetic Targets in Gynecological Tumors

Ovarian Cancer
Azienda USL Reggio Emilia - IRCCS180 enrolled1 locationNCT07169396
Recruiting
Phase 3

A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure

Biliary Tract Cancer
Sichuan Baili Pharmaceutical Co., Ltd.398 enrolled2 locationsNCT07606599
Recruiting
Phase 1

A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

Colorectal, CancerPancreatic CancerGastric Cancer+1 more
ArriVent BioPharma, Inc.405 enrolled20 locationsNCT07066657
Recruiting
Phase 1

ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas

Neurological Cancer
Massachusetts General Hospital18 enrolled3 locationsNCT03922555
Recruiting
Phase 3

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

Prostate Cancer
Novartis Pharmaceuticals940 enrolled88 locationsNCT06855277
Recruiting
Phase 2

Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Tislelizumab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally Advanced Rectal Adenocarcinoma With Low Rectal Involvement

Rectal Cancer
Affiliated Cancer Hospital of Shantou University Medical College51 enrolled2 locationsNCT07104604
Recruiting
Phase 2Phase 3

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+13 more
National Cancer Institute (NCI)224 enrolled374 locationsNCT06203600
Recruiting
Phase 2

Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)

CancerPediatric CancerDifferentiated Thyroid Cancer+1 more
Children's Hospital of Philadelphia13 enrolled5 locationsNCT06458036
Recruiting
Phase 3

A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

Metastatic Colorectal Cancer
EMD Serono Research & Development Institute, Inc.1,020 enrolled21 locationsNCT07549412
Recruiting
Phase 2

Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy

Prostate CancerRecurrent Prostate CancerPET Positive
National Cancer Institute (NCI)65 enrolled1 locationNCT06096870
Recruiting
Phase 2

Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of RAS Wild-Type mCRC

Metastatic Colorectal Cancer (CRC)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences46 enrolled1 locationNCT07724223
Recruiting
Not Applicable

Analytical Validation of Circulating DNA Analysis Methods: Creation of a Control Cohort

Healthy Volunteers (Cancer)
Institut Claudius Regaud68 enrolled1 locationNCT07663994
Recruiting

An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe

Non-small Cell Lung Cancer
Regeneron Pharmaceuticals500 enrolled49 locationsNCT05363319
Recruiting
Phase 1

A Study to Compare the Steady-State Bioavailability of Injectable Letrozole SIE and Oral Letrozole in Post-Menopausal Women With Hormone Receptor Positive Early Breast Cancer

Hormone Receptor Positive Early Breast Cancer
Rovi Pharmaceuticals Laboratories120 enrolled1 locationNCT07401381